{"nctId":"NCT00056160","briefTitle":"CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma","startDateStruct":{"date":"2003-01-01","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"count":353,"armGroups":[{"label":"CC-5013/Dex","type":"EXPERIMENTAL","interventionNames":["Drug: CC-5013","Drug: Dexamethasone"]},{"label":"Placebo/Dex","type":"EXPERIMENTAL","interventionNames":["Drug: Dexamethasone"]}],"interventions":[{"name":"CC-5013","otherNames":["lenalidomide","Revlimid"]},{"name":"Dexamethasone","otherNames":["Decadron"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.\n* No more than 3 previous anti-myeloma regimens\n* No high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg) within 6 months of study randomization.\n* Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).\n\nExclusion Criteria:\n\n* Prior development of disease progression during high-dose dexamethasone containing therapy.\n* Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm cubed\n* Laboratory abnormalities: Platelet count less than 75,000/mm cubed\n* Laboratory abnormalities: Serum creatinine greater than 2.5 mg/dL\n* Laboratory abnormalities: Serum glutamic oxaloacetic transaminase (SGOT, aspartate transaminase \\[AST\\]) or serum glutamic pyruvic transaminase (SGPT, alanine transaminase \\[ALT\\])greater than 3.0 x upper limit of normal\n* Laboratory abnormalities: Serum total bilirubin greater than 2.0 mg/dL\n* Prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for greater than or equal to 5 years.\n* Known hypersensitivity to thalidomide or dexamethasone.\n* Development of a desquamating rash while taking thalidomide.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Tumor Progression (TTP)","description":"Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.1","spread":null},{"groupId":"OG001","value":"20.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was calculated as the time from randomization to death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170.1","spread":null},{"groupId":"OG001","value":"136.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Myeloma Response","description":"The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)","description":"The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":"30.02"},{"groupId":"OG001","value":"15.0","spread":"16.98"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":111,"n":177},"commonTop":["FATIGUE","INSOMNIA","DIARRHOEA","NAUSEA","HEADACHE"]}}}